291 completed, 88 recruiting, 53 active not recruiting, 35 terminated. 163 Phase 2, 152 Phase 1, 100 Phase 3, 42 Phase 4, 16 Not applicable.
Follow Daiichi Sankyo: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] Dato-DXd, Enfortumab Vedotin (EV), Pembrolizumab - Urothelial Cancer, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 268 | 2026-10-16 | 2026-10-22 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-16 |
| A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | Not yet recruiting | Daiichi Sankyo | 600 | 2026-10-01 | 2026-09-01 |
| A Study of DS-3939a in Participants With Solid Tumors DS-3939a, Pembrolizumab, Carboplatin - Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Daiichi Sankyo | 400 | 2026-10-01 | 2026-07-31 |
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia | Phase 3 | Not yet recruiting | Daiichi Sankyo | 103 | 2026-09-30 | 2026-09-29 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 802 | 2026-09-18 | 2026-10-21 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer Patritumab deruxtecan, Trastuzumab deruxtecan - Hormone Receptor Positive, HER2-low or HER2-ultralow | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 220 | 2026-09-17 | 2026-10-01 |
| First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors DS1025a - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | Daiichi Sankyo | 45 | 2026-08-06 | 2026-08-25 |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC Dato-DXd, Rilvegostomig, Durvalumab - High-risk Muscle Invasive Urothelial Carcinoma | Phase 3 | Recruiting | AstraZeneca | 915 | 2026-07-16 | 2026-07-22 |
| A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Ifinatamab Deruxtecan - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 134 | 2026-07-06 | 2026-10-21 |
| An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) - Stomatitis | Phase 4 | Recruiting | AstraZeneca | 100 | 2026-06-24 | 2026-09-30 |
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan - Lung Neoplasm Malignant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-30 | 2026-10-01 |
| A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) I-DXd, Rescue Medication - Oesophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-03-27 | 2026-10-02 |
| A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia Combination of bempedoic acid and ezetimibe - Primary Hypercholesterolaemia, Mixed Dyslipidemia | Recruiting | Daiichi Sankyo | 2120 | 2026-03-03 | 2026-10-19 | |
| Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy Trastzumab Deruxtecan, Bevacizumab, Platinum Based Chemotherapy - Ovarian Cancer, Ovarian Carcinoma, Recurrent | Phase 2 | Recruiting | Yonsei University | 116 | 2026-02-26 | 2026-04-20 |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Gocatamig, I-DXd, Atezolizumab - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 170 | 2026-01-29 | 2026-10-20 |
| A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies DS3790a, Combination drug - Hematological Malignancies, B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 420 | 2026-01-16 | 2026-08-24 |
| A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban Edoxaban, Rivaroxaban - Atrial Fibrillation, Renal Dysfunction | Completed | Daiichi Sankyo | 8265 | 2025-12-25 | 2026-10-15 | |
| Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin Bempedoic acid, Ezetimibe, Atorvastatin - Healthy Subjects | Phase 1 | Completed | Daiichi Sankyo | 58 | 2025-12-09 | 2026-02-27 |
Showing 20 of 493. Sign in to see all of them.
Breast Neoplasms (52) · Carcinoma, Non-Small-Cell Lung (47) · Neoplasm Metastasis (29) · Diabetes Mellitus, Type 2 (26) · Atrial Fibrillation (21) · Hypertension (20) · Leukemia, Myeloid, Acute (18) · Neoplasms (18) · Ovarian Neoplasms (16) · Colorectal Neoplasms (15) · Lung Neoplasms (15) · Recurrence (15) · Coronary Artery Disease (14) · Venous Thromboembolism (12) · Diabetes Mellitus (11)
trastuzumab deruxtecan (48) · edoxaban (30) · Carboplatin (25) · Olmesartan Medoxomil (25) · patritumab deruxtecan (25) · Paclitaxel (24) · pembrolizumab (24) · Colesevelam Hydrochloride (23) · quizartinib (22) · Prasugrel Hydrochloride (19) · pexidartinib (18) · Clopidogrel (17) · Hydrochlorothiazide (15) · exatecan (13) · Capecitabine (12)
United States (356) · Spain (128) · France (117) · Italy (106) · Japan (100) · United Kingdom (96) · Germany (95) · South Korea (93) · Taiwan (86) · Canada (83) · China (76) · Belgium (72) · Poland (68) · Netherlands (62) · Brazil (58)
Robert L. DeJager, MD, FACP (13) · Guy Gammon, MB BS, MRCP (3)
PMID 31284771, PMID 29859851, PMID 33289960, PMID 18663165, PMID 18852398, PMID 22114906, PMID 31825192, PMID 32106339, PMID 33999422, PMID 35964548, PMID 37207306, PMID 37689979, PMID 38098072, PMID 38442809, PMID 38881370, PMID 40014354, PMID 40341124, PMID 40516821, PMID 40925065, PMID 41258689, PMID 12114413, PMID 12917305, PMID 16133799, PMID 16554527, PMID 16983112, PMID 17109446, PMID 17379048, PMID 17643572, PMID 17982182, PMID 18377975, PMID 18458145, PMID 18473688, PMID 18498956, PMID 18757948, PMID 18765395, PMID 19106084, PMID 19120717, PMID 19132850, PMID 19248105, PMID 19249633, PMID 19293413, PMID 19423851, PMID 19557844, PMID 19699846, PMID 19751459, PMID 19879596, PMID 20026770, PMID 20059361, PMID 20085534, PMID 20370378
2023 (35), 2025 (12), 2015 (9), 2019 (7), 2014 (5), 2016 (5), 2018 (5), 2017 (4), 2009 (2), K23DK070715 (1), R01DK078646 (1), R01DK082396 (1), R01HL063895 (1), U10CA031946 (1), U10CA180821 (1)